StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)

Equities research analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a note issued to investors on Friday. The brokerage set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a report on Wednesday, August 21st.

Arcadia Biosciences Trading Up 1.0 %

NASDAQ:RKDA opened at $2.93 on Friday. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $4.19. The company has a market cap of $3.99 million, a PE ratio of -0.57 and a beta of 1.34. The company’s 50 day moving average is $2.86 and its two-hundred day moving average is $2.67.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The company had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period last year, the firm earned ($2.64) earnings per share. As a group, analysts expect that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.